SCHEMBL3825575

SCHEMBL3825575

COc1ccc(-c2cc(=O)c3c(OC)cccc3o2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.80
ALDH1A1 P00352 9/20 0.79
KDM4E B2RXH2 7/20 0.79
CYP3A4 P08684 6/20 0.79
MAPT P10636 6/20 0.79
HSD17B10 Q99714 5/20 0.79
TP53 P04637 5/20 0.79
HPGD P15428 5/20 0.79
MEN1 O00255 5/20 0.78
KMT2A Q03164 5/20 0.78
CYP2D6 P10635 2/20 0.78
CYP2C9 P11712 2/20 0.78
CYP2C19 P33261 2/20 0.78
ABCB1 P08183 1/20 0.77
NPC1 O15118 6/20 0.67
RAB9A P51151 6/20 0.67
ABCG2 Q9UNQ0 2/20 0.67
SMN1; SMN2 Q16637 5/20 0.66
MAOB P27338 5/20 0.66
LMNA P02545 4/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7603117 0.89 AR (1.00) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL9137273 0.89 AR (0.80) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL1629391 0.88 ALDH1A1 (1.00) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL9141909 0.87 AR (0.78) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL4649207 0.87 KDM4E (1.00) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL4649423 0.87 KDM4E (0.77) ARALDH1A1KDM4ECYP3A4MAPT
SCHEMBL31675935 0.87 KDM4E (1.00) ARALDH1A1KDM4ECYP3A4MAPT
Trimethylapigenin SCHEMBL29350875 0.87 ABCB1 (1.00) ALDH1A1KDM4ECYP3A4MAPTHSD17B10
Trimethylapigenin SCHEMBL1421585 0.87 ABCB1 (1.00) ALDH1A1KDM4ECYP3A4MAPTHSD17B10
SCHEMBL30848745 0.86 AR (0.75) ARALDH1A1KDM4ECYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTRE (US) 2022-10-20 US claimed
US-20130245070-A1 COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2013-09-19 US claimed
US-20090253782-A1 Compounds for Enhancing Arginase Activity and Methods of USe Thereof CORNELL RESEARCH FOUNDATION, INC. 2009-10-08 US claimed
WO-2008011083-A2 COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF CORNELL RESEARCH FOUNDATION, INC. (US) 2008-01-24 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTRE (US) 2022-10-20 US disclosed
EP-2730431-B1 Rubber composition and tire with rubber containing flavone GOODYEAR TIRE & RUBBER (US) 2017-06-28 EP disclosed
US-9345694-B2 Compounds for enhancing arginase activity and methods of using same CORNELL RESEARCH FOUNDATION, INC. (US) 2016-05-24 US disclosed
US-20140135433-A1 TIRE WITH RUBBER CONTAINING FLAVONE THE GOODYEAR TIRE & RUBBER COMPANY (US) 2014-05-15 US disclosed
EP-2730431-A1 Rubber composition and tire with rubber containing flavone The Goodyear Tire & Rubber Company (US) 2014-05-14 EP disclosed
US-20130245070-A1 COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2013-09-19 US disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
EP-1298115-A1 PROCESS FOR THE PREPARATION OF POLYHYDRIC ALCOHOLS National Institute of Advanced Industrial Science and Technology (JP) 2003-04-02 EP disclosed
US-20020157939-A1 Process for preparation of polyhydric alcohols NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2002-10-31 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS HTR6, FOS, API5 AR 4064/4885ALDH1A1 2269/4885KDM4E 2108/4885
US-20130245070-A1 COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME ARG2, ARG1, OTC AR 4739/4885ALDH1A1 249/4885KDM4E 1426/4885
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP AR 3549/4885ALDH1A1 2440/4885KDM4E 2309/4885
US-20090253782-A1 Compounds for Enhancing Arginase Activity and Methods of USe Thereof ARG2, ARG1, OTC AR 4773/4885ALDH1A1 292/4885KDM4E 1521/4885
US-20020157939-A1 Process for preparation of polyhydric alcohols ADH1C, ADH1A, ADH5 AR 4061/4885ALDH1A1 315/4885KDM4E 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.